• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Pernix Therapeutics Holdings, Inc. (PTX)

    -NasdaqGM
    0.44 Down 0.01(2.81%) May 27, 4:00PM EDT
    |After Hours : 0.42 Down 0.02 (4.21%) May 27, 7:28PM EDT
    ProfileGet Profile for:
    Pernix Therapeutics Holdings, Inc.
    10 North Park Place
    Suite 201
    Morristown, NJ 07960
    United States - Map
    Phone: 800-793-2145
    Fax: 862-260-8752
    Website: http://www.pernixtx.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:274

    Business Summary 

    Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products. The company’s products comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; and Khedezla, a prescription medication for major depressive disorder. Its product also include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro and Rezira for the relief of cough and nasal congestion; Vituz, a hydrocodone bitartrate and chlorpheniramine maleate combination oral solution for the treatment of cough and allergies associated with the common cold; and OMECLAMOX-PAK, a gastroenterology product. The company sells its products through its sales force and third-party sales organizations, as well as through its subsidiaries. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Pernix Therapeutics Holdings, Inc.

    Corporate Governance 
    Pernix Therapeutics Holdings, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 10. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. John Anthony Sedor , 71
    Chairman, Interim Chief Exec. Officer and Member of Nominating Committee
    70.00KN/A
    Mr. Sanjay Patel CFA, 40
    Chief Financial Officer
    516.00K0.00
    Mr. Terence S. Novak , 60
    Chief Operating Officer
    498.00K0.00
    Mr. Barry J. Siegel , 51
    Sr. VP, Gen. Counsel and Sec.
    391.00K0.00
    Mr. Michael J. Golembiewski ,
    Principal Accounting Officer, VP and Corp. Controller
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders